A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: INCA034176
DRUG: Best Available Therapy (BAT)

Sponsor

Incyte Corporation